Zydus Cadila declared that it has bagged nod from USFDA to sell Losartan Potassium tabs and Losartan Potassium + HCTZ tabs in the United States.

The company will sell Losartan Potassium in three different potencies including 25mg, 50mg and 100mg.

On the other hand, the company will market Losartan Potassium + HCTZ tabs in potencies of 50/12.5mg and 100/25mg.

The medications come under anti hypertensive segment and are used for the treatment of hypertension.

In US, the sales of Losartan Potassium stood at $1.3 billion, while sales of Losartan Potassium + HCTZ tabs is estimated at $944 million in 2010. As per reports, Zydus Nycomed`s new facility at Navi Mumbai will manufacture 11 active pharmaceutical ingredients.

Zydus Nycomed is a JV between Zydus Cadila and Nycomed, which was set up in the year 1998 to make key starting materials for Nycomed`s heart-burn medication Pantoprazole.

The stock of the company opened at Rs 695 on the Bombay Stock Exchange (BSE).

At 3:38 p. m., the share value declined 1.3%at Rs 684.55.

The share price has seen a 52-week high of Rs 72.50 and a low of Rs 320.16 on BSE.

Current EPS & P/E ratio stood at 29.33 and 23.34 respectively.